Novel Tissue-Engineered Amniotic Dressing for Chronic Wound Healing.

Abstract

Chronic wounds represent a worldwide challenge, often proving difficult to heal with currently available treatments. This report introduces a novel tissue-engineered amniotic dressing, AmGel, used for treating chronic wounds in two patients. Prepared by integrating amniotic membrane with natural biopolymers, AmGel demonstrates excellent biocompatibility and safety, offering a safe, efficacious, and user-friendly therapeutic solution for chronic wounds. The aim of this study was to conduct a preliminary evaluation of the safety and effectiveness of this tissue-engineered amniotic dressing. Both patients achieved over an 80% wound healing rate within six weeks of treatment with AmGel, with complete wound closure occurring after twelve weeks. No adverse events were reported during the treatment period. This study describes the details of the clinical cases and provides an overview of the current evidence on the use of AmGel dressings in clinical practice.